Open Access

Enhanced aerobic exercise performance in women by a combination of three mineral Chelates plus two conditionally essential nutrients

  • Robert A. DiSilvestro1Email author,
  • Staci Hart1,
  • Trisha Marshall1,
  • Elizabeth Joseph1,
  • Alyssa Reau1,
  • Carmen B. Swain2 and
  • Jason Diehl3
Journal of the International Society of Sports Nutrition201714:42

https://doi.org/10.1186/s12970-017-0199-2

Received: 5 August 2017

Accepted: 5 November 2017

Published: 13 November 2017

Abstract

Background

Certain essential and conditionally essential nutrients (CENs) perform functions involved in aerobic exercise performance. However, increased intake of such nutrient combinations has not actually been shown to improve such performance.

Methods

For 1 mo, aerobically fit, young adult women took either a combination of 3 mineral glycinate complexes (daily dose: 36 mg iron, 15 mg zinc, and 2 mg copper) + 2 CENs (daily dose: 2 g carnitine and 400 mg phosphatidylserine), or the same combination with generic mineral complexes, or placebo (n = 14/group). In Trial 1, before and after 1 mo, subjects were tested for 3 mile run time (primary outcome), followed by distance covered in 25 min on a stationary bike (secondary outcome), followed by a 90 s step test (secondary outcome). To test reproducibility of the run results, and to examine a lower dose of carnitine, a second trial was done. New subjects took either mineral glycinates + CENs (1 g carnitine) or placebo (n = 17/group); subjects were tested for pre- and post-treatment 3 mile run time (primary outcome).

Results

In Trial 1, the mineral glycinates + CENs decreased 3 mile run time (25.6 ± 2.4 vs 26.5 ± 2.3 min, p < 0.05, paired t-test) increased stationary bike distance after 25 min (6.5 ± 0.6 vs 6.0 ± 0.8 miles, p < 0.05, paired t-test), and increased steps in the step test (43.8 ± 4.8 vs 40.3 ± 6.4 steps, p < 0.05, paired t-test). The placebo significantly affected only the biking distance, but it was less than for the glycinates-CENs treatment (0.2 ± 0.4. vs 0.5 ± 0.1 miles, p < 0.05, ANOVA + Tukey). The generic minerals + CENs only significantly affected the step test (44.1 ± 5.2 vs 41.0 ± 5.9 steps, p < 0.05, paired t-test) In Trial 2, 3 mile run time was decreased for the mineral glycinates + CENs (23.9 ± 3.1 vs 24.7 ± 2.5, p < 0.005, paired t-test), but not by the placebo. All changes for Test Formula II or III were high compared to placebo (1.9 to 4.9, Cohen’s D), and high for Test Formula II vs I for running and biking (3.2 & 3.5, Cohen’s D).

Conclusion

In summary, a combination of certain mineral complexes plus two CENs improved aerobic exercise performance in fit young adult women.

Keywords

MineralsConditionally essential nutrientsRunningStationary bikingStep test

Background

Micronutrient functions are needed for aerobic exercise. Therefore, aerobic performance should be helped by optimal intake of these nutrients including trace minerals. For instance, iron, even apart from its role in hemoglobin, affects aerobic energy metabolic pathways through functions in enzymes and cytochromes [1]. Another trace mineral, copper, is part of cytochrome c oxidase, the terminal enzyme in aerobic energy metabolism [1]. Other copper enzymes work against oxidative stress [1], which contributes to exercise-induced fatigue [2]. A third trace mineral, zinc, could affect aerobic exercise performance in a variety of ways: indirect antioxidant actions [35], a cofactor role in carbonic anhydrase that eliminates carbon dioxide [6, 7], a cofactor role in lactate dehydrogenase [6], and an activator of enzymes in energy metabolism [6].

For active young adult women, intake of these 3 minerals may often fall below optimal amounts. For iron, it well documented that exercising women often get a degree of deficiency [8]. Severe deficiency causes anemia, but even milder deficits could affect energy metabolism [9]. For copper, in young adult women, supplemental copper has improved copper function [10]. For zinc, in one USA diet survey, for about 40% of the women, intake fell below the RDA [11]. Moreover, the zinc RDAs may not even be set high enough [12, 13]. Multiple studies [1, 1215] find low intake of zinc in active people. This low intake especially applies to participants in sports that need weight control, people who avoid animal products, and people eating high carbohydrate, low fat and protein diets. Furthermore, exercise training may raise copper and zinc requirements [14, 16, 17]. This situation may not be fixed easily by all multi-vitamin-mineral supplements since many use zinc and copper oxide, which are not the best absorbed forms [4].

On a related note, increased zinc or copper intake might benefit exercise performance even in non-deficient situations. In a controlled feeding study, eating above the copper RDA improves cycling performance and muscle cytochrome c oxidase versus RDA intake [18]. For zinc, in a rat study [19], plasma lactate level after swimming is highest in a low zinc diet group, medium in a zinc adequate group, and lowest in a zinc supplemented group. In similar work, moderately high zinc intake can raise lung levels of glutathione, an antioxidant, in swim trained rats [5].

Besides essential minerals, conditionally essential nutrients (CENs) also hold relevance to exercise. These molecules are both made by the body and eaten [1]. Traditionally, intake has been studied mostly for people with health problems i.e. [20]. However, in healthy rats or mice [21, 22], supplementation with the CEN carnitine delays exercise-induced fatigue. In humans, supplementing this same agent can influence muscle recovery, which can enhance training effects on exercise performance [23]. Carnitine can theoretically affect exercise performance and recovery via a role in fat oxidation for energy [24] and possibly via an anti-ischemic effect [25]. Another CEN, phosphatidylserine, could affect exercise performance by neuroendocrine effects, enzyme cofactor functions, and anti-inflammatory actions [26, 27]. Supplementation with this CEN influences perceived fatigue during exercise [28]. In addition, phosphatidylserine supplementation can extend time to exhaustion in a long biking session in active males [29]. The effects on other types of exercise measures in other types of exercisers await further research.

A new study tested the following hypothesis: increased intake of three trace minerals in well absorbed forms, plus two CENs, will improve aerobic exercise performance in recreationally trained, young adult women. The primary outcome was 3 mile runtime; secondary outcomes were distance covered in 25 min stationary biking and step number in a 90 s step test, both done shortly after the run. Positive results would show that increased trace mineral intake and/or CENs can improve aerobic exercise performance in aerobically active women. Later studies can further define the minimal combination of the 5 nutrients needed to produce the effects.

Methods

Participants

Subjects were non-smoking female, aged 18–30, with no injuries that restricted the ability to do aerobic exercise, and no acute major health problems or chronic conditions that affect energy metabolism or oxidative stress (ie anemia, diabetes, and cancer). Subjects were recreationally, aerobically trained in that they were not competitive athletes, but had regularly done aerobic exercise training at least120–180 min per week for at least 6 mo, with at least 2 days per week consisting of runs of 3 miles or more. All of these inclusion/exclusion criteria were evaluated based on answers to questions on an eligibility questionnaire. The subjects selected for study were instructed to maintain their current dietary and exercise practices.

Procedures-trial 1

Subjects underwent exercise performance tests before and after a supplement intervention of 1 mo (N = 42). Subjects were randomly assigned to a supplement intervention in a double blind fashion. For Trial 1, subjects took a powder mixed by the research team. This team obtained the nutrients directly from suppliers who reported a third party analysis. The subjects were provided with a measuring spoon to add one serving to a beverage consumed just before or after a meal. The subjects could select the beverage, but it had to be one that they already consumed regularly. Low Calorie soft drinks or water + sweetener were the most common choices. Subjects split the daily dose into 2 servings. Assignments were as follows (n = 14/group):

Placebo (corn starch)

Test Formula I: 36 mg iron as ferrous sulfate, 2 mg copper as copper gluconate, 15 mg zinc as zinc gluconate, 2 g carnitine as carnitine tartrate (Carnipure® donated by Lonza, Basel, Switzerland), and 400 mg phosphatidylserine (SerinAid® donated by Chemi Nutra, Austin, TX).

Test Formula II: 36 mg iron as iron bisglycinate (Ferrochel® donated by Albion), 2 mg copper as copper glycinate (Albion), 15 mg zinc as zinc glycinate (Albion), 2 g carnitine as Carnipure® (Lonza), and 400 mg phosphatidylserine as SerinAid® (Chemi Nutra).

Exercise testing consisted of the following:
  • Time for a 3 mile run (also used for Trial 2)

  • Distance covered in 25 min of stationary cycling in the manual mode, done after a post-run walk for 200 m in about 1 min 30 s; the biking test used a resistance level determined on a day prior to the testing. If during the first testing, the subject felt the resistance setting was too hard or too easy, it was changed once. During the second testing, the times used at each resistance were repeated.

  • A 90 s step test done about 1.5 min after the cycling; subjects walked during the 1.5 min recovery; results were total steps completed with alternating lead legs; the step test was done on a permanent bleacher area near the running track (step height of 41 cm).

Procedures-trial 2

A new group of subjects (N = 34) was examined to look at run result reproducibility and a half dose of Carnipure® carnitine (1 g/day). Exercise testing consisted of time in a 3 mile run done before and after a 1 mo supplement intervention. For this Trial, subjects were given capsules. The minerals were combined into one capsule by Albion; the carnitine and phosphatidylserine capsules were purchased commercially. All products, including the purchased ones, had independent analysis of the contents. Random assignments were as follows (n = 17/group):

Placebo (corn starch)

Test Formula III-same as II, but with half the Trial 1 carnitine dose (capsules from Now Foods, Bloomingdale, IL), and phosphatidylserine as Cogni-PS® (Jarrow Formulas, Los Angeles, CA).

Statistical analyses

Data are presented as mean or mean change ± SD. For the change data, 95% confidence intervals are included in the figure legends. Confidence intervals were calculated at http://www.fon.hum.uva.nl/Service/CGI-Inline/HTML/Statistics/Student_t_Test.html. For other statistical analysis, significance was set at p < 0.05. For each measure, for each of the treatment groups, post-intervention results were compared to pre-intervention results by paired t-test (http://www.fon.hum.uva.nl/Service/Statistics/Student_t_Test.html). For further statistical analysis, the results for each measure were expressed as the change in values (post intervention value – pre-intervention value). For Trial 1, where indicated, the changes in Test Formula II were compared to the changes in either of the other 2 groups by 1 way ANOVA + Tukey multiple comparison test (http://statistica.mooo.com/OneWay_Anova_with_TukeyHSD). For Trial 2, Test Formula III changes were compared to placebo by unpaired t-test (http://www.fon.hum.uva.nl/Service/CGI-Inline/HTML/Statistics/2Sample_Student_t_Test.html). For all changes in values, size effects were evaluated using Cohen’s D values using: http://www.socscistatistics.com/effectsize/Default3.aspx.

Results

The data sets reported here were complete and did not exclude any data. Based on placebo data from Trial 1, the primary outcome, running times, showed good reliability based on a paired t-test >0.05, an intraclass correlation coefficient of 0.97 and a coefficient of variation of 3.6%. Test Formula II produced a substantial, statistically significant mean decrease in 3 mile run time of 54 s (p < 0.05, paired t-test, Table 1). When the data was expressed as the decrease in run times (Fig. 1), a 95% confidence interval did not come close to crossing 0 for Test Formula II, but did cross 0 for the placebo. For Test Formula I, the 95% confidence interval just missed crossing 0. The change for Test Formula II differed significantly from that produced by placebo or Test Formula I (Fig. 1). The size effects for Test Formula II were large compared to the other two groups (Cohen’s D of 2.7 vs placebo and 3.2 vs Test Formula I).
Table 1

Run times pre- and post-treatments

 

Placebo

Test Formula I

Test Formula II

Run-Pre

26.6 ± 3.3

26.8 ± 3.5

26.5 ± 2.3

Run-Post

26.5 ± 3.3

26.6 ± 3.4

25.6 ± 2.4*

Test Formula I contains the generic minerals. Test Formula II contains the glycinate minerals. Run times are means of minutes ± SD. *p < 0.05 versus pre-value, paired t-test, two tailed

Fig. 1

Decrease in run time after each of three treatments. Test Formula I contained generic minerals. Test Formula II contained glycinate minerals. Run times are mean decreases in min ± SD. The 95% confidence intervals for placebo, Test Formula 1, and Test Formula II were ±9.1, 5, and 9.4 respectively. *p < 0.05 versus either of the other two treatments

For the biking test, distance covered was increased significantly by both placebo and Test Formula II based on paired t-test (Table 2). Thus, reliability for this secondary outcome was not as strong as for the primary outcome. Even so, when the data was expressed as the change in distance (Fig. 2), the 95% confidence interval was just outside crossing 0 for the placebo, and touched 0 for Test Formula I. In contrast, the 95% confidence interval did not come close to crossing 0 for Test Formula II. The mean change for the bike distance was greater for the Test Formula II vs the placebo or Test Formula I (Fig. 2). The size effects for Test Formula II were large compared to the other two groups (Cohen’s D of 1.9 vs placebo and 3.5 vs Test Formula I).
Table 2

Stationary bike distance covered pre- and post-treatments

 

Placebo

Test Formula I

Test Formula II

Bike-Pre

6.2 ± 0.8

6.1 ± 1.1

6.0 ± 0.8

Bike-Post

6.5 ± 0.9*

6.3 ± 1.1

6.5 ± 0.6*

Bike distances are mile means ± SD. *p < 0.05, versus pre-value, paired t-test, two tailed

Fig. 2

Increase in stationary bike distance after each of three treatments. Test Formula I contained generic minerals. Test Formula II contained glycinate minerals. Distances are mean increases in miles ± SD. The 95% confidence intervals for placebo, Test Formula 1, and Test Formula II were ±0.12, 0.12, and 0.05 respectively. *p < 0.05 versus either of the other two treatments

Based on placebo data from Trial 1, the secondary outcome of the step test, showed good reliability based on a paired t-test >0.05, an intraclass correlation coefficient of 0.98 and a coefficient of variation of 3.2%. Test Formula I produced an increase that was significant by a one-tailed, paired t-test (p < 0.05, Table 3). Test Formula II treatment produced an increase that was strongly significant by a two-tailed, paired t-test (p < 0.005, Table 3). When the data was expressed as the change in steps (Fig. 3), a 95% confidence interval did not cross 0 for Test Formula I or II and was just outside crossing 0 for the placebo. The average change for the step test was greater for the both Test Formula groups versus placebo, but not versus each other (p < 0.05 versus placebo, 1 way ANOVA + Tukey multiple comparisons, Fig. 3). The size effects for Test Formula II were large compared to placebo, but small versus Test Formula I (Cohen’s D of 2.5 vs placebo and 0.4 vs Test Formula I).
Table 3

Step test pre- and post-treatments

 

Placebo

Test Formula 1

Test Formula II

Steps-Pre

40.7 ± 7.0

41.0 ± 5.9

40.3 ± 6.4

Steps-Post

42.3 ± 6.4

44.1 ± 5.2*

43.8 ± 4.8**

Steps are number of step up means ± SD. *p < 0.05 versus pre-value, paired t-test, one tailed; **p < 0.005 versus pre-value, paired t-test, two tailed

Fig. 3

Increase in steps after each of three treatments. Test Formula I contained generic minerals. Test Formula II contained glycinate minerals. Step changes are mean increases in steps ± SD. The 95% confidence intervals for placebo, Test Formula 1, and Test Formula II were ±0.5, 0.8, and 0.5 respectively. *p < 0.05 versus placebo, but not versus each other (ANOVA + Tukey multiple comparisons)

A new group of subjects was examined to look at reproducibility of the run results and to test a lower dose of carnitine (Trial 2). Test Formula III, but not placebo, significantly decreased run time by paired t-test (p < 0.005, Table 4). The mean decrease was 41 s, which differed from placebo to a highly significant degree by unpaired t test (p = 0.001, Fig. 4). The mean time for the placebo actually increased, though this was not significant by paired t-test (Table 4). However, for the change in run time, the 95% confidence interval did not cross 0 for the placebo’s increase in time (Fig. 4). For the Test Formula III decrease in run time, the 95% confidence interval did not come close to 0. Also, the size effects for Test Formula III were large compared to placebo (Cohen’s D of 4.9).
Table 4

Run times pre- and post-treatments, Trial 2

 

Placebo

Test Formula III

Run-Pre

23.2 ± 2.7

24.7 ± 2.5

Run-Post

23.4 ± 2.9

23.9 ± 3.1*

Run times are means ± SD; Test Formula III (half the carnitine dose of Test Formula I and II). *p < 0.005 versus pre-value, paired t-test, two tailed

Fig. 4

Change in run time after each of two treatments. Run time changes are means ± SD; The 95% confidence intervals for placebo, Test Formula 1, and Test Formula III were ±4.1 and 4.3 respectively. *p = 0.001, unpaired t-test, two tailed

Discussion

The results of this study demonstrated that a combination of essential and conditionally essential micronutrients can strongly improve aerobic exercise performance. The particular nutrient combination tested here was chosen partly in light of the subjects studied, namely young adult women who are recreationally trained in aerobic exercise. For other types of subjects, the micronutrient mixture used here may or may not show the same efficacy as seen in the present study. Also, it is not known if all 5 micronutrients given here were needed for the effect. However, what the current study does shows is that aerobic exercise performance can respond to some type of increased micronutrient intake.

Replacement of the mineral glycinates with more standard mineral complexes restricted two of the three positive exercise effects. One of these substitutions was copper gluconate for copper glycinate. Copper gluconate has not shown effects in two non-exercise studies [30, 31]. In contrast, in a number of studies i.e. [10, 32, 33], copper glycinate has changed parameters such as copper enzyme activities and oxidized LDL readings. Zinc gluconate was also substituted for zinc glycinate. The former has produced effects in some studies i.e. [34], but not in some others i.e. [35]. In two studies, zinc glycinate has shown better bioactivity than zinc gluconate [35, 36]. In the one other substitution, ferrous sulfate was used instead of ferrous bisglycinate. The former is considered a standard form of iron for supplementation and has been effective [4]. The glycinate form of iron has shown a little better performance under some circumstances i.e. [4, 3739] and may be better tolerated [4, 39]. Also, in a small unpublished study (DiSilvestro, RA), the 3 mineral glycinates used in this study increase plasma readings for the iron protein ferritin better than a combination of 3 other forms of the same minerals.

This study’s effects occurred in response to a sustained intake of nutrients rather than an acute pre-workout intake. However, the sustained ingestion was not tremendously long (1 mo). This timeframe was chosen because copper, iron and zinc nutritional status can all change in response to 1 mo or less of increased intake i.e. [3, 4, 38, 40, 41]. Similarly, carnitine supplementation can change metabolic responses to exercise in mice or humans in 1–3 weeks [21, 23]. Also, 10 day supplementation with phosphatidylserine alters cortisol response to exercise [27].

The exercise portion of the Trial 1was designed to produce three fatigue points in under an hour. This same exercise protocol was used in two previous studies from our group [42, 43]. The two previous studies examined an acute carbohydrate intervention before and during the exercise. In those cases, no effects were seen for the 3 mile run, but improvements were seen in the two subsequent exercise segments. A simple explanation for the previous results could be that substantial glycogen depletion had to start occurring before the intervention effect begins. In the present study, in both trials, an effect was seen in the run time results. Thus, in the present intervention, some mechanisms differed from those seen with the carbohydrate interventions.

In Trial 2, a good effect was seen for run time, though the mean decrease fell below that of Trial 1. This might have resulted simply from random variation. Another possibility was that changing the type of phosphatidylserine between trials diminished effectiveness to some degree. Another possible issue was that the daily carnitine dose was halved from 2 g to 1 g. However, this change probably exerted no effect. In a previous study, 2 g of carnitine was above a saturating dose for plasma levels [44]. Also, in an exercise recovery study with carnitine tartrate, a 1 and 2 g carnitine dose gave the same effects [45].

Conclusions

In summary, this study showed that a combination of micronutrients can improve aerobic exercise performance in one set of circumstances. These findings justify further research on various combinations of micronutrients on exercise performance.

Abbreviations

CENs: 

Conditionally essential nutrients

Declarations

Acknowledgements

The authors gratefully recognize the following for help with exercise performance monitoring: Erin Baldinger, Rheadon Remy, Kelly Mackessy, Autumn Zimmerman, Lisa DiSilvestro, and David DiSilvestro.

Funding

Trial 1 was funded by a grant from the Gatorade Sports Science Institute to RAD.

Availability of data and materials

Individual identifiable data cannot be communicated due to terms of the project consent form. General data can be obtained from the lead author (RAD) for justified reasons.

Authors’ contributions

RAD secured funding and oversaw the whole project. SH helped design logistics and other aspects of the research, and took a major role in collecting data. TM had a primary role in data collection and supervision of research for Trial 1. EJ take a lead role in screening potential subjects and organizing data for Trial 1. AR supervised most of the research in Trial 2. CS and JD gave input on various aspects of subject participation in the research and were principal investigators on the human subject protocol for Trial 1 and 2, respectively. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The research protocol was approved by the Ohio State University Human Subjects Biomedical Institutional Review Board (Protocols 2007H0157 and 2011H0381). All participants signed informed consent forms that included permission to publish group results.

Consent for publication

This does not apply since the manuscript contains no individual or identifying data.

Competing interests

Some of the nutritional ingredients were donated as noted in the Methods. At the time the research was conducted, none of the authors had any competing interests. At present, Robert DiSilvestro, as president of Columbus Nutraceutical Formulations LLC, has a financial interest in a product derived from the research described here.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Human Nutrition, The Ohio State University
(2)
Kinesiology, The Ohio State University
(3)
OSU Sports Medicine, The Ohio State University

References

  1. Wardlaw GM, Hampl JS, DiSilvestro RA. Perspectives in nutrition. 6th ed. New York: McGraw Hill; 2004.Google Scholar
  2. Reid MB. Free radicals and muscle fatigue: of ROS, canaries, and the IOC. Free Radic Biol Med. 2008;44:169–79.View ArticlePubMedGoogle Scholar
  3. DiSilvestro RA. Zinc in relation to diabetes and oxidative disease. J Nutr. 2000;130:1509S–11S.PubMedGoogle Scholar
  4. DiSilvestro RA. Handbook of minerals as nutritional supplements. Boca Raton: CRC Press; 2005.Google Scholar
  5. Ozturk A, Baltaci AK, Mogulkoc R, Oztekin E, Sivrikaya A, Kurtoglu E, Kul A. Effects of zinc deficiency and supplementation on malondialdehyde and glutathione levels in blood and tissues of rats performing swimming exercise. Biol Trace Elem Res. 2003;94:157–66.View ArticlePubMedGoogle Scholar
  6. Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiol Rev. 1993;73:79–118.PubMedGoogle Scholar
  7. Lukaski HC. Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise. Am J Clin Nutr. 2005;81:1045–51.PubMedGoogle Scholar
  8. Beard J, Tobin B. Iron status and exercise. Am J Clin Nutr. 2000;72:594S–7S.PubMedGoogle Scholar
  9. Burden RJ, Morton K, Richards T, Whyte GP, Pedlar CR. Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis. Br J Sports Med. 2015;49:1389–97.View ArticlePubMedGoogle Scholar
  10. DiSilvestro RA, Selsby J, Siefker K. Copper supplementation effects on plasma F2α-isoprostanes and urinary collagen crosslinks in young adult women. J Trace Elem Med Biol. 2010;24:165–8.View ArticlePubMedGoogle Scholar
  11. Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin a, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy Press; 2001.Google Scholar
  12. Sandstead H, Freeland-Graves J. Dietary phytate, zinc and hidden zinc deficiency. J Trace Elem Med Biol. 2014;28:414–7.View ArticlePubMedGoogle Scholar
  13. Armah SM. Fractional zinc absorption for men, women, and adolescents is overestimated in the current dietary reference intakes. J Nutr. 2016;146:1276–80.View ArticlePubMedGoogle Scholar
  14. Micheletti A, Rossi R, Rufini S. Zinc status in athletes, relation to diet and exercise. Sports Med. 2001;31:577–82.View ArticlePubMedGoogle Scholar
  15. Singh A, Deuster P, Moser P. Zinc and copper status in women by physical activity and menstrual status. J Sports Med Phys Fitness. 1990;30:29–36.PubMedGoogle Scholar
  16. DiSilvestro R, Hinchcliff K, Blostein-Fujii A. Sustained strenuous exercise in sled dogs depresses three blood copper enzyme activities. Biol Trace Elem Res. 2005;105:87–96.View ArticlePubMedGoogle Scholar
  17. Kikukawa A, Kobayashi A. Changes in urinary zinc and copper with strenuous physical exercise. Aviat Space Environ Med. 2002;73:991–5.PubMedGoogle Scholar
  18. Lukaski HC, Johnson PE. Dietary copper (cu) at the recommended intake decreases muscle cytochrome c oxidase (CCO) activity and alters metabolic responses during exercise in men. FASEB J. 2005;19:A982.Google Scholar
  19. Baltaci A, Ozyurek K, Mogulkoc R, Kurtoglu E, Ozkan Y, Celik I. Effects of zinc deficiency and supplementation on the glycogen contents of liver and plasma lactate and leptin levels of rats performing acute exercise. Biol Trace Elem Res. 2003;96:227–36.View ArticlePubMedGoogle Scholar
  20. Kendler BS. Supplemental conditionally essential nutrients in cardiovascular disease therapy. J Cardiovasc Nurs. 2006;21:9–16.View ArticlePubMedGoogle Scholar
  21. Kim J, Pan J, Lee E, Kim Y. L-Carnitine enhances exercise endurance capacity by promoting muscle oxidative metabolism in mice. Biochem Biophys Res Commun. 2015;464:568–73.View ArticlePubMedGoogle Scholar
  22. Pandareesh M, Anand T. Ergogenic effect of dietary L-carnitine and fat supplementation against exercise induced physical fatigue in Wistar rats. J Physiol Biochem. 2013;69:799–809.View ArticlePubMedGoogle Scholar
  23. Huang A, Owen K. Role of supplementary L-carnitine in exercise and exercise recovery. Med Sport Sci. 2012;59:135–42.View ArticlePubMedGoogle Scholar
  24. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol. 2007;581:431–44.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Katircioglu SF, Grandjean PA, Kucuker S, Saritas Z, Yavas S, Tasdemir O, Bayazit K. Effects of carnitine on preconditioned latissimus dorsi muscle at different burst frequencies. J Card Surg. 1997;12:120–5.View ArticlePubMedGoogle Scholar
  26. Kingsley M. Effects of phosphatidylserine supplementation on exercising humans. Sports Med. 2006;36:657–69.View ArticlePubMedGoogle Scholar
  27. Starks M, Starks S, Kingsley M, Purpura M, Jäger R. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr. 2008;5:11.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Wells AJ, Hoffman JR, Gonzalez AM, Stout JR, Fragala MS, Mangine GT, McCormack WP, Jajtner AR, Townsend JR, Robinson EH. Phosphatidylserine and caffeine attenuate postexercise mood disturbance and perception of fatigue in humans. Nutr Res. 2013;33:464–72.View ArticlePubMedGoogle Scholar
  29. Kingsley M, Miller M, Kilduff L, McEneny J, Benton D. Effects of phosphatidylserine on exercise capacity during cycling in active males. Med Sci Sports Exerc. 2006;38:64–71.View ArticlePubMedGoogle Scholar
  30. Nielsen F, Lukaski H, Johnson L, Roughead Z. Reported zinc, but not copper, intakes influence whole-body bone density, mineral content and T score responses to zinc and copper supplementation in healthy postmenopausal women. Br J Nutr. 2011;106:1872–9.View ArticlePubMedGoogle Scholar
  31. Pratt W, Omdahl J, Sorenson J. Lack of effects of copper gluconate supplementation. Am J Clin Nutr. 1985;42:681–2.PubMedGoogle Scholar
  32. DiSilvestro RA, Joseph E, Raimo A, Kim YM. Copper supplementation effects on blood copper enzymes and plasma cardiovascular health markers in middle aged people. Metabolism. 2012;61:1242–6.View ArticlePubMedGoogle Scholar
  33. Jones AA, DiSilvestro RA, Coleman M, Wagner TL. Copper supplementation of adult men: effects on blood copper enzyme activities & indicators of cardiovascular disease risk. Metabolism. 1997;46:1380–3.View ArticlePubMedGoogle Scholar
  34. Shah U, Abu-Shaheen A, Malik MA, Alam S, Riaz M, Al-Tannir M. The efficacy of zinc supplementation in young children with acute lower respiratory infections: a randomized double-blind controlled trial. Clin Nutr. 2013;32:193–9.View ArticlePubMedGoogle Scholar
  35. DiSilvestro RA, Koch E, Rakes L. Moderately high dose zinc Gluconate or zinc Glycinate: effects on plasma zinc and erythrocyte superoxide dismutase activities in young adult women. Biol Trace Elem Res. 2015;168:11–4.View ArticlePubMedGoogle Scholar
  36. Gandia P, Bour D, Maurette JM, Donazzolo Y, Duchène P, Béjot M, Houin G. A bioavailability study comparing two oral formulations containing zinc (Zn bis-glycinate vs. Zn gluconate) after a single administration to twelve healthy female volunteers. Int J Vitam Nutr Res. 2007;77:243–8.View ArticlePubMedGoogle Scholar
  37. Layrisse M, García-Casal MN, Solano L, Barón MA, Arguello F, Llovera D, Ramírez J, Leets I, Tropper E. Iron bioavailability in humans from breakfasts enriched with iron bis-glycine chelate, phytates and polyphenols. J Nutr. 2000;130:2195–9.PubMedGoogle Scholar
  38. Pineda O, Ashmead H. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition. 2001;17:381–4.View ArticlePubMedGoogle Scholar
  39. Szarfarc S, de Cassana L, Fujimori E, Guerra-Shinohara E, de Oliveira I. Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulfate in the control of iron deficiency in pregnant women. Arch Latinoam Nutr. 2001;51S:42–7.Google Scholar
  40. Bales CW, DiSilvestro RA, Currie K, Plaisted CS, Joung H, Galanos AN, Lin P. Marginal zinc deficiency in older adults: responsiveness of zinc status indicators. J Amer Coll Nutr. 1994;13:455–62.View ArticleGoogle Scholar
  41. DiSilvestro RA, Marten JT, Skehan M. Effects of copper supplementation on ceruloplasmin and copper-zinc superoxide dismutase activities in free-living rheumatoid arthritis patients. J Amer Coll Nutr. 1992;11:177–80.Google Scholar
  42. DiSilvestro RA, Joseph E, Hart S, Swain CM. Effects of a mixed nutraceutical beverage on performance of moderately strenuous aerobic exercise lasting under an hour. Nutraceutical J. 2011;4:151–5.View ArticleGoogle Scholar
  43. DiSilvestro RA, Joseph E, Marshall T, Hart S, Swain CB. Effects of Gatorade® on performance of moderately strenuous aerobic exercise lasting under an hour. FASEB J. 2011;25:587.11.Google Scholar
  44. Bain M, Milne R, Evans A. Disposition and metabolite kinetics of oral L-carnitine in humans. J Clin Pharmacol. 2006;46:1163–70.View ArticlePubMedGoogle Scholar
  45. Spiering B, Kraemer W, Vingren JL, Hatfield DL, Fragala MS, Ho J, Maresh CM, Anderson JM, Volek J. Responses of criterion variables to different supplemental doses of L-carnitine L-tartrate. J Strength Cond Res. 2007;21:259–64.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017